Clinical impact and cost‐saving analysis of a comprehensive pharmaceutical care intervention in older patients with cancer

Author:

Herledan Chloé12ORCID,Falandry Claire34,Huot Laure56,Poletto Nicolas1,Baudouin Amandine1,Cerfon Marie‐Anne1,Lorsche Laurie3,Bret Judith3,Ranchon Florence12,Rioufol Catherine12

Affiliation:

1. Department of Pharmacy, Groupement Hospitalier Sud Hospices Civils de Lyon Pierre‐Bénite France

2. EA 3738, CICLY Centre pour l'Innovation en Cancérologie de Lyon Université Lyon 1 Oullins France

3. Institut du Vieillissement Hospices Civils de Lyon Lyon France

4. Laboratoire CarMeN, INSERM U1060/ INRAE U1397/Université Lyon 1 Université de Lyon Pierre‐Bénite France

5. Hospices Civils de Lyon, Pôle de Santé Publique Service Evaluation Economique en Santé Lyon France

6. Inserm U1290 Research on Healthcare Performance (RESHAPE) Université Lyon 1 Lyon France

Abstract

AbstractBackgroundHospital admission and discharge are at high risk of drug‐related problems (DRPs) in older patients with cancer. This study aimed to assess the clinical and economic impact of a comprehensive pharmaceutical care intervention (RECAP) to optimize drug therapy in patients with cancer ≥75 years admitted to oncology or geriatric wards.MethodRECAP intervention was defined as follows: at admission and discharge, hospital pharmacists conducted comprehensive medication reconciliation and review, identified relevant DRPs and provided optimization recommendations to prescribers; at discharge, pharmacists also provided patient education and shared information with primary care providers. The impact of the intervention was assessed by the rate of implementation of recommendations by the prescribers and the evolution of polypharmacy rate; a peer review of the clinical significance of DRPs was performed by an expert panel of geriatric oncologists and pharmacists. A cost saving analysis compared cost avoided through resolution of DRPs to cost of pharmacist's time.ResultsFrom January 2019 and August 2020, 201 patients were included (median age 80 [75–97] years), 68.7% with solid tumors. DRPs requiring optimization were identified in 70.9% of patients at admission (mean 1.7 DRP/patient) and 47.7% at discharge (0.9 DRP/patient). Most pharmacist recommendations (70.8%) were followed by prescribers, allowing the correction of 1.2 DRP/patient at admission and 0.7 DRP/patient at discharge. Half of resolved DRPs were rated as clinically significant. However, polypharmacy rate was not reduced at discharge. Cost comparison showed $7.2 avoided for $1 invested, with an estimated total net benefit of $354,822 (mean $1766 per patient).ConclusionsThe RECAP model significantly reduces DRPs in hospitalized older patients with cancer. The model was cost saving, confirming the value of implementing it in routine practice.

Publisher

Wiley

Subject

Geriatrics and Gerontology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3